CCIA
XLRN

Campbell & Co Investment Adviser’s Acceleron Pharma XLRN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,180
Closed -$208K – 503
2020
Q2 		$208K Buy
+2,180
New +$210K 0.26% 211
2018
Q3 		– Sell
-7,200
Closed -$349K – 568
2018
Q2 		$349K Buy
+7,200
New +$262K 0.27% 144

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Campbell & Co Investment Adviser's XLRN Position: Q3 2020 in Review

Campbell & Co Investment Adviser sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 2,180 shares — an estimated $208K sold.

Campbell & Co Investment Adviser first reported a position in XLRN in Q2 2018 and held it in 2 quarters. The position peaked at $349K in Q2 2018. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

  • Campbell & Co Investment Adviser reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 2,180 Acceleron Pharma shares in Q3 2020, an estimated $208K.
  • Campbell & Co Investment Adviser first reported a position in Acceleron Pharma in Q2 2018 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Acceleron Pharma position peaked at $349K in Q2 2018.
  • 238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2020, filed 15 Oct 2020.